Urea Cycle Disorder Treatment Market to Grow by USD 215.4 Million (2024-2028), Driven by Rising Prevalence, with AI Redefining Market Landscape - Technavio

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 12/03/2024.
  • Additional Information
    • Alternate Title:
      technavio-Research
    • Subject Terms:
      New York; United States of America; United Kingdom
    • Abstract:
      NEW YORK, Dec. 3, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global urea cycle disorder treatment market size is estimated to grow by USD 215.4 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.2% during the forecast period. Increasing prevalence of urea cycle disorder is driving market growth, with a trend towards increasing growth potential in emerging economies. However, low access to specialized care poses a challenge. Key market players include Abbott Laboratories, Acer Therapeutics Inc., Aeglea BioTherapeutics Inc., Arcturus Therapeutics Holdings Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, CAMP4, Dipharma SA, Eurocept B.V., Horizon Therapeutics Plc, Immedica Pharma AB, Medunik USA, Nestle SA, Orpharma Pty Ltd., Reckitt Benckiser Group Plc, Recordati S.p.A, RELIEF THERAPEUTICS Holding SA, Swedish Orphan Biovitrum AB, Synlogic Inc., and Ultragenyx Pharmaceutical Inc.. [ABSTRACT FROM PUBLISHER]